Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• One of the following hematologic malignancies/disorders:
• * Acute lymphoblastic leukemia
• * In second or subsequent complete remission (CR)
• * In first CR with high-risk features (e.g., Philadelphia chromosome-positive)
• * In first relapse and failed conventional salvage therapy
• * Acute myelogenous leukemia (AML)
• * In second or subsequent CR
• * In early first relapse
• * In full first relapse and failed conventional salvage therapy
• * In first CR with high-risk features, e.g., trisomy 8 or FAB 6/7
• * Standard-risk AML offered conventional-dose consolidation chemotherapy or autologous bone marrow transplantation
• * Chronic myelogenous leukemia in chronic, accelerated, or second chronic phase
• * No blast crisis
• * Severe aplastic anemia that has failed at least 1 course of immunosuppressive therapy
• * Paroxysmal nocturnal hemoglobinuria with high-risk features (e.g., disseminated intravascular coagulation, thrombotic events)
• * Myelodysplastic syndrome, i.e.:
• * Symptomatic, transfusion-dependent refractory anemia with excess blasts
• * (RAEB) or RAEB in transformation
• * Secondary leukemia in CR following conventional-dose induction chemotherapy
• Unrelated marrow donor available who is 8 out of 10-, 9 out of 10-, or 10 out of 10-antigen serologically HLA-matched at A, B, C, DRb, and DQB loci by molecular typing
• No CNS malignancy
• PATIENT CHARACTERISTICS:
• Age:
• 17 to 60
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• No reduction due to other serious illness
• Hematopoietic:
• Not specified
• Hepatic:
• Bilirubin less than 3 mg/dL
• AST/ALT no greater than twice normal
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Creatinine clearance greater than 60 mL/min
• Cardiovascular:
• Left ventricular ejection fraction at least 45%
• No severe hypertension
• Pulmonary:
• DLCO, FEV\_1, and FVC at least 50%
• Other:
• HIV negative
• No active infection at time of transplant
• No advanced diabetes
• No significant neurologic deficit
• No active drug or substance abuse
• No emotional disorders
• Able to participate in frequent medical care for at least 1-2 years
• Willing to comply with National Marrow Donor Program policies
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• Chemotherapy
• See Disease Characteristics
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified